Marrone Bio Innovations — Merger or Acquisition (March 2022)
16 slides from Marrone Bio Innovations's merger presentation, Mar 17, 2022

Slide 1: Crop Solutions Transaction presentation
<2 “Crop Solutior Transaction presenta

Slide 2: Certain Information
Certain Information ‘mis Pesiratn is fe orien) puptes ay an dots net crate sete vation eho satan cf on ft 6 buy ek 8 ‘Mronmenstan a pschve any at sents ase Se onan mama te Coron an alae, nasa et ne (Fhe petriaton ua or prt ete deomnay of eco wien! fe per cant of he Gorpary © paid By aap He ‘estan on

Slide 3: Transaction Key Highlights
Transaction Key Highlights @© Merger creates a global leader in the agriculture biologicals market Combined revenues +$300M growing at a +20% CAGR over the past 4 years Business will be fully integrated from product discovery, to active ingredient manufacturing, to commercialization and distribution

Slide 4: Deal Summary
Deal Summary © Allstock transaction - MBI! shareholders will receive 0.088 BIOX common shares for each MBII share © Transaction structure - Reverse triangular merger. Upon closing of the transaction, MBII will become a wholly owned subsidiary of BIOX Timing - Expected to close during 30 calendar 202

Slide 5: Companies Overview
Companies Overview @ Bioceres Crop Solutions Nasdaq: BIOX Fully-integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality and wheat * Global footprint with sales in 39 countries, including 8 subsidiaries and a leading presence in

Slide 6: Marrone Investment Opportunity
Marrone Investment Opportunity © Industry leading product portfolio with a well- invested pipeline ~$145M 1 Total amount Potential near-term invested in R&D in _product launches last 10 years © Rapid growth with significant improvement in profitability » Stand alone business nearing breakeven point

Slide 7: Biological Growth Opportunity
Biological Growth Opportunity Biological growth is expected to significantly outpace the industry Xo) © Strong demand pull from growers, regulators, and consumers looking for natural, safer and more sustainable food inputs © Well positioned to serve the massive market opportunity from the replacemen

Slide 8: Combined Biological Portfolio
Combined Biological Portfolio a®& Complementary portfolios cover all major ag biological categories Combined © Portfolio of products with over +$100M"in Speci Bioceres Marrone rtfolio microbial revenues covering most applications (foliar sprays, seed treatments and soil Portfolio Bio-insecticides ap

Slide 9: Combination Creates Global Distribution Coverage
Combination Creates Global Distribution Coverage Strong commercial footprint across key agricultural markets PROPRIETARY Combined proprietary distribution channel with +700 retailers STRATEGIC PARTNERSHIPS Strategic partnerships with key players in the seed care industry HB4 HB4 soy and wheat as a b

Slide 10: Upcoming Pipeline Commercial Launches
Upcoming Pipeline Commercial Launches Portfolios complement and extend visible organic growth potential Key upcoming commercial launches": 2021 2022 2023 HB4 Wheat MBI 306 HB4 Soy Bioherbicides & OHB4 MBI 306 WHEAT & SOY Unlocks 100% bio-based seed Only available drought-tolerant treatments solution

Slide 11: Financial Synergies
Financial Synergies © Cost synergies (target achievement within 12 months) of $8M'’ Bioceres Crop Solutions Eliminating duplicative public company costs Integrating teams and leveraging commercial $ Million best practices Leverage manufacturing footprints to drive operating efficiencies 278.0 @ Reve

Slide 12: Rizobacter Case Study
Rizobacter Case Study xo) Roadmap for success $ Million 240.3 @ Entrepreneurial organization with strong IP culture @ Unleashed commercial potential of the business eee while keeping the leadership team largely intact 1 @ Established KPIs, empowered leadership and 93.4 ' brought in additional financ

Slide 13: Financing Update
Financing Update ao @ Financial synergies in combination with dry powder availability provide more than sufficient resources to execute on the long-term vision, including both the HB4 and biological opportunities ® Combined cash position of $58.5M BIOX $39.9" MBII $18.62 @ Capital commitment for up

Slide 14: Innovations
Innovations ‘onebio.com fa Bioceres Crop Solutions \ : Marrone’ “7 Z CO one 7 Z 14

Slide 15: Appendix: Marrone Bio Adj. EBITDA reconciliation
Appendix | @o Marrone Bio Adj. EBITDA reconciliation Marrone Bio cy18 cy19 CY20 LTM 3Q21 S Million Net loss (31.1) (30.9) (20.2) (37.2) (20.2) (15.5) Taxes - - - - 0.03 (0.05) Interest expense 73 TA 25 1.5 1.4 15 Depreciation and amortization 2.2 2.0 19 23, 3.6 3.5 Stock based compensation Qa 2a 19.

Slide 16: Appendix II: BIOX and Rizobacter Adj. EBITDA reconciliation
Appendix II BIOX and Rizobacter Adj. EBITDA reconciliation Bioceres Crop Solutions FY18 S$ Million Profit for the period (14.3) Income tax (10.9) Finance results 41.0 Depreciation and amortization 44 Inventory purchase price allocation charge 23 Stock-based compensation 0.03 Transaction expenses and
Source: SEC EDGAR · 425 filed Mar 17, 2022